When was Geneticure founded?

Geneticure was founded in 2012 and raised its 1st funding round 4 years after it was founded.

Where is Geneticure located?

Geneticure is headquartered in Minnetonka, United States.

How many employees does Geneticure have?

As of May 31, 2026, the latest employee count at Geneticure is 9.

Is Geneticure a funded company?

Geneticure is a funded company, having raised a total of $1.12M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 20, 2016.

When was the latest funding round of Geneticure?

Geneticure's latest funding was a $***** Seed round on Apr 05, 2017, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.3B in funding in 2026 to date.

Where does Geneticure rank among its competitors?

Geneticure ranks 50th amongst 1073 active competitors, of which 249 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Respiree, which secured an undisclosed amount in Feb, 2026.

Who are the top competitors of Geneticure?

Geneticure's top competitors include Eko, Endotronix and HBOX. Among them, Respiree secured the most recent funding round in February, 2026.

Geneticure - 2026 Company Profile, Team, Funding & Competitors

Geneticure is a seed company based in Minnetonka (United States), founded in 2012 by Eric Snyder, Thomas Olson, Scott Snyder and Ryan Sprissler. It operates as a Personalized hypertension treatment through DNA analysis for better medication selection. Geneticure has raised $1.12M in funding from M25. The company has 1073 active competitors, including 249 funded and 81 that have exited. Its top competitors include companies like Eko, Endotronix and HBOX.

Company Details

Personalized hypertension treatment through DNA analysis for better medication selection. This company is dedicated to personalizing the treatment of hypertension and other chronic diseases. They provide clinicians with tools to personalize therapy based on a patient's unique DNA, leveraging genomics and integrative physiology to develop tests that help patients recover faster and more cost-effectively. Their approach aims to reduce trial-and-error in medication selection, guiding physicians to prescribe the right treatment from the start. They focus on precision medicine, pharmacogenomics, and pharmacogenetics to offer clinical decision support for high blood pressure management. Their innovative solutions have the potential to improve patient outcomes and reduce healthcare costs, making a significant impact on the management of chronic conditions.

Website: geneticure.com
Social

Key Metrics

Founded Year

2012

Location

Minnetonka, United States

Stage

Seed

Total Funding

$1.12M in 3 rounds

Latest Funding Round

Seed, Apr 05, 2017, $*****

Investors

M25 & 2 more

Ranked

50^th among 1073 active competitors

Employee Count

9 as on May 31, 2026

Similar Companies

Endotronix & 1148 more

View Geneticure's full profile

Geneticure is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Geneticure Inc. CIN: 471738934 , United States, Active	Dec 31, 2011	-	-	-

Geneticure has raised a total funding of $1.12M over 3 rounds. Its first funding round was on May 20, 2016. Its latest funding round was a Seed round on Apr 05, 2017 for $*****. 1 investor participated in its latest round. Geneticure has 3 institutional investors.

Here is the list of recent funding rounds of Geneticure:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 05, 2017	5890752	Seed	8802270	3181905	2782151	1917387
Oct 12, 2016	6684390	Seed	7453105	6091275	1790938	8354320
May 20, 2016	1364756	Seed	5159858	6722610	1010524	2703439

Access funding benchmarks and valuations. Sign up today!

View details of Geneticure's funding rounds and investors

The founders of Geneticure are Eric Snyder, Thomas Olson, Scott Snyder and Ryan Sprissler.

Here are the details of Geneticure's key team members:

Eric Snyder: Co-founder & COO of Geneticure. They serve on the boards of 2 companies.
Contact Info: 1 email address
Thomas Olson: Co-founder & Chief Clinical Officer of Geneticure.
Scott Snyder: Co-Founder & President of Geneticure.
Contact Info: 1 email address
Ryan Sprissler: Co-Founder & CSO of Geneticure.
Contact Info: 1 email address

View details of Geneticure's Founder profiles and Board Members

Geneticure's employee count trend

Geneticure has 9 employees as of May 26. Here is Geneticure's employee count trend over the years:

Uncover Geneticure's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Geneticure include Eko, Endotronix and HBOX. Here is the list of Top 10 competitors of Geneticure, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Eko 2012, Oakland (United States), Series D	Provider of AI-based remote patient monitoring platform for cardiac health	$195M	Artis Ventures, EDBI & 34 others	72/100
2nd	Endotronix 2007, East Peoria (United States), Acquired	Provider of device for Measurement of Hemodynamic parameters for heart failure maangement	$155M	Life Sciences Partners, Seroba Life Sciences ... & 14 others	65/100
3rd	HBOX 2020, Boston (United States), Seed	Provider of a SaaS-based remote patient monitoring platform and devices for healthcare professionals	$1.7M	Arali Ventures, Eterna Growth Partners & 2 others	62/100
4th	Hilo 2018, Neuchatel (Switzerland), Series B	Provider of continuous blood pressure monitoring devices and associated app	$100M	Redalpine, TransLink Capital & 13 others	61/100
5th	PathogenDX 2014, Tucson (United States), Series B	Provider of DNA-based pathogen testing kits	$11.6M	Entourage Effect Capital, Altitude Investment Management ... & 11 others	61/100
6th	Biobeat 2014, Petah Tikva (Israel), Series B	Body vitals monitoring solution	$51M	Orbimed, Ally Bridge Group & 5 others	61/100
7th	Somatix 2015, New York City (United States), Acquired	Provider of an AI-based remote health monitoring tool	$21.2M	Digitalis Ventures, New York Digital Health ... & 5 others	61/100
8th	Openwater 2016, San Francisco (United States), Series C	Provider of imaging technologies for medical diagnosis and treatments	$100M	Khosla Ventures, Bold Capital Partners & 10 others	60/100
9th	Respiree 2018, Singapore (Singapore), Series A	Provider of AI and sensors-based post care solutions	$15M	She1K, Clavystbio & 21 others	60/100
10th	Neteera 2014, Jerusalem (Israel), Series B	Provider of a contactless remote patient monitoring platform	$28.2M	Aescuvest, Foxconn Electronics & 9 others	60/100
50th	Geneticure 2012, Minnetonka (United States), Seed	Personalized hypertension treatment through DNA analysis for better medication selection	$1.12M	M25, Wireframe Ventures & 1 others	47/100